YOU DECIDE:
PATIENTS SELF-ADMINISTER AT HOME OR YOU ADMINISTER IN OFFICE

Recommended dosing schedules1:

MODERATE-TO-SEVERE ASTHMA WITH AN EOSINOPHILIC PHENOTYPE

OCS-DEPENDENT ASTHMA PATIENTS, OR PATIENTS WITH CO-MORBID MODERATE-TO-SEVERE ATOPIC DERMATITIS, FOR WHOM DUPIXENT IS INDICATED

  • Initial dose is 600 mg (two 300 mg pre-filled syringes) followed 2 weeks later by
    every-other-week dosing of a 300 mg pre-filled syringe

DUPIXENT is intended for use under the guidance of a healthcare provider. A patient may self-inject DUPIXENT after training in subcutaneous injection technique using the pre-filled syringe. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use.

  • DUPIXENT can be administered in the office under the guidance of a healthcare provider if the patient is not an appropriate candidate for self-administration
  • a 300 mg=2 mL solution.
  • b 200 mg=1.14 mL solution.
NOW APPROVED
The DUPIXENT 300 mg
Pre-filled Pen will be
available by late August
2020
for appropriate
patients aged 12 years
and older!
DUP.20.05.0112

Reference:

  1. DUPIXENT Prescribing Information.